ResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.
Follow RMD
ResMed Inc. (RMD) Return on equity
ResMed Inc.'s return on equity over the twelve months to 30 June 2026 was 24.3%. Over the past ten years it has ranged from 15.7% (fiscal 2018) to 27.2% (fiscal 2020); the current reading is higher than 75% of that period. That is above the Medical Instruments & Supplies industry median of −1.32% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | 24.3% | (1.59) |
| FY2025 | 25.9% | 3.16 |
| FY2024 | 22.7% | (1.26) |
| FY2023 | 24.0% | (1.00) |
| FY2022 | 25.0% | 7.33 |
| FY2021 | 17.6% | (9.58) |
| FY2020 | 27.2% | 7.62 |
| FY2019 | 19.6% | 3.89 |
| FY2018 | 15.7% | (3.03) |
| FY2017 | 18.7% | (2.74) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| SOLV Solventum Corporation compare | 34.0% |
| RMD ResMed Inc. | 24.3% |
| WST West Pharmaceutical Services, Inc. compare | 19.1% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| BDX Becton, Dickinson and Company compare | 3.77% |
| ALC Alcon compare | 2.94% |
| RGEN Repligen Corporation compare | 1.99% |
| MDLN Medline Inc. compare | 0.00% |
| BAX Baxter International Inc. compare | −15.8% |
| Medical Instruments & Supplies industry median | −1.32% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement